Zanubrutinib Plus Venetoclax Shows Promise in Del(17p)/TP53-Mutated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Zanubrutinib plus venetoclax delivered promising preliminary efficacy results in newly diagnosed CLL/SLL in participants with del(17p) and/or TP53 mutations....